Phase 3 Readout

FATE: Phase 3 Topline: Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or

Name: Phase 3 Topline: Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or
Start: 2027-01-01
End: 2027-01-01

January 1, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: January 1, 2027
Company: FATE THERAPEUTICS INC (FATE)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or

January 1, 2027

FATE overview →

Company: FATE THERAPEUTICS INC (FATE)
Indication: Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma; Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7; Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7